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Major depressive disorder is one of the most common mental
disorders. Many patients with major depressive disorder
experience one or more relapses or recurrences.1 For patients with
recurrent depression, maintenance antidepressant medication
(mADM) helps to reduce the risk of relapse/recurrence.2–4 Hence,
clinical guidelines typically recommend that they should continue
their medication for at least 1 or 2 years.5,6 Although mADM can
be effective, it has several disadvantages. First, patients often
experience side-effects5 and long-term adherence is typically
low.7 Second, the protective effects of mADM do not persist after
discontinuation whereas psychological interventions appear to
have long-term beneficial effects.8 In addition, many patients
prefer psychological treatment.9 Therefore, developing alternative
strategies for prevention of depressive relapse/recurrence is
important. Mindfulness-based cognitive therapy (MBCT) is an
innovative psychological approach for relapse/recurrence
prevention in recurrent depression developed by Segal, Williams
& Teasdale.10 It is an 8-week group-based treatment that integrates
elements from mindfulness-based stress reduction (MBSR)11 and
cognitive–behavioural therapy (CBT).12 A meta-analysis13 showed
that MBCT reduces the 12-month relapse/recurrence risk
compared with usual care or placebo, with a relative risk reduction
of 43%, in patients with a history of three or more episodes of
depression. Based on this evidence, MBCT is recommended for
patients in remission who are at high risk of depressive relapse/
recurrence.6,14 In their meta-analytic paper, Piet & Hougaard13
also addressed the comparison between MBCT and mADM, based
on two studies15,16 with a total of 177 participants. For patients
with a history of three or more depressive episodes, MBCT with
discontinuation of mADM was at least as effective as mADM
alone in reducing relapse/recurrence (risk ratio (RR) = 0.80, 95%
CI 0.60–1.08). This finding has recently been replicated in a large
trial including 424 patients.17 These findings suggest that MBCT
could be a viable alternative to mADM for patients who would like
to withdraw from their medication. However, previous trials did
not directly compare MBCTalone with the combination of MBCT
and mADM. Therefore, the main aim of this multicentre, non-
inferiority effectiveness trial was to examine whether patients
who receive MBCT for recurrent depression in remission could
safely withdraw from mADM, i.e. without increased relapse/
recurrence risk, compared with the combination of these inter-
ventions. Patients were randomly allocated to MBCT followed
by discontinuation of mADM or MBCT+mADM. The study
had a follow-up of 15 months. Our primary hypothesis was that
discontinuing mADM after MBCT would be non-inferior, i.e.
would not lead to an unacceptably higher risk of relapse/
recurrence, compared with the combination of MBCT+mADM.
In addition, we explored whether there was a difference between
the groups in terms of time to relapse/recurrence, severity of
(residual) depressive symptoms during follow-up, number,
duration and severity of relapse/recurrence, and quality of life.
Method
The study design and procedures are presented in full in the study
protocol18 (ClinicalTrials.gov: NCT00928980). They are described
in brief below. Originally we intended to conduct a three-armed
randomised controlled trial (RCT) of MBCT alone, mADM alone
or MBCT+mADM, but this turned out to be too complicated
because of strong treatment preferences expressed by patients.
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Background
Mindfulness-based cognitive therapy (MBCT) and
maintenance antidepressant medication (mADM) both
reduce the risk of relapse in recurrent depression,
but their combination has not been studied.
Aims
To investigate whether MBCT with discontinuation of mADM
is non-inferior to MBCT+mADM.
Method
A multicentre randomised controlled non-inferiority trial
(ClinicalTrials.gov: NCT00928980). Adults with recurrent
depression in remission, using mADM for 6 months or longer
(n=249), were randomly allocated to either discontinue
(n=128) or continue (n=121) mADM after MBCT. The
primary outcome was depressive relapse/recurrence within
15 months. A confidence interval approach with a margin of
25% was used to test non-inferiority. Key secondary
outcomes were time to relapse/recurrence and depression
severity.
Results
The difference in relapse/recurrence rates exceeded the
non-inferiority margin and time to relapse/recurrence was
significantly shorter after discontinuation of mADM. There
were only minor differences in depression severity.
Conclusions
Our findings suggest an increased risk of relapse/recurrence
in patients withdrawing from mADM after MBCT.
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Therefore, we decided to conduct two parallel RCTs: an RCT
comparing MBCT followed by discontinuation of mADM v.
MBCT+mADM for patients wanting MBCT (current trial), and
an RCT comparing MBCT+mADM v. mADM alone for patients
wanting to hold on to their medication19 (parallel trial). Thereby
we acknowledged patients’ preferences while maintaining the
experimental rigor of randomisation. This change has been
described in the study protocol.18 The study was approved by the
Medical Ethics Committee Arnhem-Nijmegen (nr. 2008/242) for
all participating sites. After a complete description of the study,
written informed consent was obtained from all participants.
Participants
Patients were recruited in 12 secondary and tertiary psychiatric
out-patient clinics across The Netherlands between September
2009 and January 2012. Patients were referred by mental health-
care professionals or recruited by advertisements in the media
(television, magazines and newspapers). Inclusion criteria were a
history of at least three depressive episodes according to the
DSM-IV;20 in full or partial remission, defined as not currently
meeting the DSM-IV criteria for major depressive disorder;
currently treated with antidepressants for at least 6 months; 18
years of age or older; and Dutch speaking. Exclusion criteria were:
bipolar disorder; any primary psychotic disorder (current and
previous); clinically relevant neurological/somatic illness; current
alcohol or drug dependency; high dosage of benzodiazepines
(42mg lorazepam equivalents daily); recent electroconvulsive
therapy (53 months ago); previous MBCT and/or extensive
meditation experience (for example retreats); current psychological
treatment with a frequency of more than once per 3 weeks; and
inability to complete interviews and self-report questionnaires.
Procedure
Eligibility was assessed with the Structured Clinical Interview for
DSM-IV (SCID) Axis 1 Disorders21 in a research interview
performed by independent, trained research assistants. Eligible
patients were randomly assigned to MBCT followed by guided
discontinuation of mADM (‘MBCT+discontinuation’) or to
MBCT with continuation of mADM (‘MBCT+mADM’).
Randomisation was performed using a website-based application,
developed specifically for this study by an independent statistician,
with a minimisation procedure per research centre, stratified for
full v. partial remission (scoring respectively 411 or 411 on
the Inventory of Depressive Symptomatology – Clinician rated
(IDS-C)22,23), number of past episodes (3–4 v. 55), prior CBT
(yes/no) and gender. Allocation was performed with a 1:1 ratio.
Randomisation took place after the clinical interview and
participants were informed about the assigned treatment
immediately by the research assistant. The research assistants
conducting the assessments could not be masked to treatment
group since they were also involved in the practical organisation of
the trial. The baseline assessment took place after randomisation and
participants started MBCT within 2 months of randomisation.
The date of the first scheduled MBCT was considered the start
date of the study. Follow-up assessments took place 3, 6, 9, 12
and 15 months after this start date. Participants were assessed to
the end of the follow-up period irrespective of relapse/recurrence.
The assessments took place between September 2009 and June 2013.
Interventions
MBCT+discontinuation group
MBCT was largely based on the protocol by Segal, Williams &
Teasdale24 with some adaptations. The intervention consisted of
8 weekly sessions of 2.5 h (instead of 2 h) and 1 day of silent
practice between the sixth and seventh session (which originates
from the MBSR curriculum11 and is suggested in the most recent
version of the MBCT protocol10). It was delivered in groups of
8–12 participants. MBCT included formal meditation exercises,
such as the body scan, sitting meditation, walking meditation
and mindful movement as well as informal exercises, such as
bringing present-moment awareness to everyday activities.
Cognitive–behavioural techniques included education, monitoring
and scheduling of activities, identification of negative automatic
thoughts and devising a relapse prevention plan. Participants were
encouraged to practice meditation at home for about an hour a
day using CDs.
MBCT was provided in 12 different centres across The
Netherlands, with a total of 19 teachers and 111 MBCT courses.
Groups were mixed comprising patients from both treatment
groups as well as patients not included in the trial. Videotapes
of the MBCT sessions were available for 15 teachers. Two tapes
per teacher were randomly selected. Teacher competency was
examined by two independent expert raters using the
Mindfulness-Based Interventions: Teaching Assessment Criteria
comprising six domains.25 We report the average rating of these
domains on a scale from 1 to 6 (incompetent, beginner, advanced
beginner, competent, proficient, advanced).
Patients were asked and recommended to withdraw gradually
from their antidepressants over a period of 5 weeks, starting after
the seventh session of MBCT. This was supervised by psychiatrists.
A protocol for medication tapering developed for this study by
two experts in pharmacological treatment of major depressive
disorder (W.A.N. and M.B.J.B.) was provided. For discontinuation
we recommended a minimum of 3 and a maximum of 12
consultations during the follow-up period. Adherence to the study
protocol was defined as attending four or more MBCT sessions, as
in previous studies,15,26 and having fully discontinued mADM
before the 6-month follow-up assessment (i.e. within 6 months
after baseline and within approximately 3–4 months after the last
MBCT session).
MBCT+mADM group
MBCT was provided as described above. For continuation of
mADM, a minimum of one consultation with a psychiatrist was
recommended. Psychiatrists were instructed to maintain or
reinstate an adequate dose of antidepressants, and recommendations
to manage side-effects were provided. Adherence to the study
protocol was defined as attending four or more MBCT sessions
and using a therapeutic dose of mADM at each follow-up contact
during the observed time period (using last observation carried
forward for participants who did not complete all assessments).
Outcome measures
Primary outcome
The primary outcome measure was relapse/recurrence as
measured with the SCID-I by trained research assistants every 3
months during the follow-up period.18 We purposively selected
a sample of audiotaped SCID-I interviews (n=35) across all study
centres and across different levels of depression severity (mild,
moderate or severe). These were rated by masked raters. The
interrater agreement between first and second ratings was found
to be substantial (kappa (k) = 0.70, 95% CI 0.46–0.94, P=0.001).27
Secondary outcomes
Time to relapse/recurrence was calculated in weeks from the start
of the study until the start of the first relapse/recurrence. Patients
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whose follow-up data were unavailable or who did not experience
a relapse/recurrence before the end of the follow-up period were
treated as censored observations (with relapse/recurrence status
set at 0 (‘no’) and time to event set at the number of weeks in
the study with a maximum of 65 weeks). Severity of (residual)
depressive symptoms was measured with the Dutch version of
the IDS-C22 at every assessment during the 15-month follow-up
period. The IDS-C has good psychometric qualities.23,28 In
addition, number of relapses/recurrences (1 v. 41) and duration
(in weeks) and severity (mild, moderate or severe) of the first
relapse/recurrence were examined.
Quality of life was assessed at baseline, 3 and 15 months using
the 26-item self-report WHOQOL short version.29 The WHOQOL
assesses subjective quality of life in four domains: physical,
psychological, social and environmental. Two questions with
regard to overall perception of quality of life and health are
included as well.
Statistical analysis
For the sample size calculation we refer to the published protocol.18
In line with this protocol, we first report analyses based on
intention-to-treat (ITT), followed by per-protocol analyses. The
ITTsample included all participants as randomised; the per-protocol
sample included those participants who adhered to both treatment
protocols (see ‘Interventions’). For the primary outcome
(relapse/recurrence) we calculated the one-sided 95% confidence
interval of the difference in relapse/recurrence rates between the
groups using R version 3.1.1. To conclude non-inferiority, the
upper margin of the 95% confidence interval, i.e. the maximum
difference between groups within this 95% confidence interval,
should not exceed our non-inferiority margin of 25%. In line with
regulatory guidelines on non-inferiority trials,30,31 this should be
the case for both ITT and per-protocol, as per-protocol analysis
may be more conservative in non-inferiority studies. In addition,
a generalised linear model using a binomial family with an
identity link was used to compare relapse/recurrence rates.
Differences in time to relapse/recurrence were analysed using a
Cox regression proportional hazards model using SPSS 20.0.
Regression analyses were performed with and without adjustment
for depressive symptoms at baseline and number of depressive
episodes in the past (Log transformed), factors known to predict
relapse/recurrence.32 As there were no effects of research site on
relapse/recurrence, we did not include this factor in our statistical
models. Severity of (residual) depressive symptoms (IDS-C)
during the 15-month follow-up period was analysed using a latent
growth curve model in MPlus version 7 with six time points, a
random intercept and a random slope for group. Participants
who did not complete all assessments were included in the
analyses using full information maximum likelihood estimation
for missing data.
In patients who had a relapse/recurrence, number and severity
were analysed using Pearson w2 tests. Differences in duration of
(first) relapse/recurrence were analysed with independent-samples
t-tests. Quality of life was analysed with a repeated-measures
ANOVA for both the observed data-set and the imputed data-
set, using multiple imputation for missing data. Moderation
analyses were performed using Cox regression analyses for the
stratification factors (a) full v. partial remission, (b) number of
prior depressive episodes (3 or 4 v. 5+), (c) prior CBT (yes v.
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Table 1 Baseline demographic and clinical characteristics of patients with recurrent depression receiving mindfulness-based
cognitive therapy (MBCT) followed by discontinuation of maintenance antidepressant medication (MBCT+discontinuation) or MBCT
plus maintenance antidepressant medication (MBCT+mADM)
MBCT+discontinuation group MBCT+mADM group
Variable ITT (n=128) Per-protocol (n=67) ITT (n=121) Per-protocol (n=68)
Women, n (%) 92 (72) 52 (78) 76 (63) 40 (59)
Educational level, n (%)
Low 9 (7) 6 (9) 8 (7) 5 (7)
Middle 40 (31) 19 (28) 25 (21) 13 (19)
High 73 (57) 41 (61) 81 (67) 48 (71)
Missing 6 (5) 1 (2) 7 (6) 2 (3)
Marital status, n (%)
Single 31 (24) 17 (25) 25 (21) 14 (21)
Married/cohabiting 72 (56) 38 (57) 69 (57) 44 (65)
Divorced/widowed 20 (16) 11 (16) 21 (17) 9 (13)
Missing 5 (4) 1 (2) 6 (5) 1 (1)
Employed, n (%) 84 (66) 50 (75) 75 (62) 39 (57)
Remission, n (%)
Full, IDS-C 411 70 (55) 40 (60) 63 (52) 31 (46)
Partial, IDS-C >11 58 (45) 27 (40) 58 (48) 37 (54)
Type of mADM, n (%)
Selective serotonin reuptake inhibitor 92 (72) 53 (79) 98 (81) 54 (79)
Tricyclic antidepressants 26 (20) 11 (16) 16 (13) 10 (15)
Othera 10 (8) 3 (5) 7 (6) 4 (6)
Previous cognitive–behavioural therapy treatment, n (%) 76 (59) 36 (54) 72 (60) 40 (59)
Suicide attempt (lifetime), n (%) 25 (20) 14 (21) 22 (18) 13 (19)
Age, years: mean (s.d.) 50.7 (10.6) 50.0 (11.3) 49.9 (10.5) 50.6 (10.7)
Baseline depression (IDS-C), mean (s.d.) 12.6 (9.6) 10.9 (8.6) 12.6 (10.5) 13.5 (10.2)
Number of previous episodes, mean (s.d.) 5.9 (5.3) 6.0 (5.3) 5.6 (4.1) 5.5 (3.5)
Age at major depressive disorder onset,b mean (s.d.) 25.0 (11.7) 26.9 (12.1) 25.0 (11.8) 25.9 (12.6)
ITT, intention-to-treat; IDS-C, Inventory of Depressive Symptomatology – Clinician rated.
a. Including serotonin–noradrenaline reuptake inhibitors, monoamine oxidase inhibitors and mirtazapine.
b. Based on self-report.
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no), and (d) gender. Probability values lower than 0.05 were
considered significant for all analyses.
Results
Patient characteristics, flow and adherence
Table 1 shows the baseline demographic and clinical characteristics
of the participants (MBCT+discontinuation group: n= 128,
MBCT+mADM group: n=121). There were no major imbalances
between the groups. Within the MBCT+discontinuation group,
patients who did not adhere to the protocol, i.e. attending fewer
than four MBCT sessions and/or staying on medication, had
higher levels of residual depressive symptoms at baseline (14.4,
s.d. = 10.5) than those who followed the protocol (10.9,
s.d. = 8.6; t=2.09, P=0.04, d= 0.37).
Figure 1 shows the flow of participants from screening to
analysis. Follow-up assessments were incomplete for 74/249
participants (30%) of which 41/249 (16%) did not complete any
follow-up assessment. Adherence to MBCT was higher in the
MBCT+discontinuation group (116/128, 91%) than in the
MBCT+mADM group (96/121, 79%; w2 = 6.26, P= 0.01). The
number of patients adhering to the discontinuation regimen
was 68/128 (53%) and 78/121 patients (64%) adhered to the
continuation regimen (w2 = 3.30, P= 0.07). No unexpected harms
were reported.
The teacher competency ratings showed that none of the
teachers was incompetent, two teachers (13%) were characterised
as beginners, six (40%) as advanced beginners, four (27%) as
competent, three (20%) as proficient, and none as advanced.
The mean teacher competency score was 3.5 (s.d. = 0.9, range
2.0–5.2). Further details will be published elsewhere.
Primary outcome: relapse/recurrence
In the ITT sample, 69/128 participants in the MBCT+discontin-
uation group (54%) and 47/121 in the MBCT+mADM group
(39%) experienced a relapse/recurrence (RR= 1.38, 95% CI
1.05–1.83). The upper margin of the one-sided 95% confidence
interval of the difference between the groups was 25.3%, which
exceeded our predefined non-inferiority margin of 25% (Fig. 2).
In the per-protocol sample, relapse/recurrence during the 15-month
follow-up occurred in 46/67 patients (69%) randomised to
MBCT+discontinuation compared with 31/68 patients (46%)
randomised to MBCT+mADM (RR= 1.5, 95% CI 1.11–2.05).
The upper margin of the one-sided 95% confidence interval was
36.7%, which also exceeded the non-inferiority margin. This
implies that non-inferiority could not be shown. In addition,
relapse/recurrence rates were significantly different between the
groups for the ITT sample (Wald w2 = 5.81, P=0.02) and for the
per-protocol sample (Wald w2 = 7.76, P= 0.005).
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. 78 (64%) Continued mADM
17 (14% Reduced mADM
14 (12%) Discontinued mADM
12 (10% No information owing to dropout
. 96 (79%) Completed 54 MBCT sessions
. 68 (56%) Adhered to both interventions
38 (31%) Lost to follow-up:
. 3 months: 19 (16%)
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. 9 months: 6 (5%)
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121 Analysed intention-to-treat
. 53 Excluded from per-protocol analysis
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128 MBCT+Discontinuation
. 68 (53%) Discontinued mADM
2 (2%) Discontinued mADM after 6 months
17 (13%) Reduced mADM
30 (23%) Continued mADM
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. 116 (91%) Completed 54 MBCT sessions
. 67 (52%) Adhered to both interventions
36 (28%) Lost to follow-up:
. 3 months: 22 (17%)
. 6 months: 3 (2%)
. 9 months: 1 (1%)
. 12 months: 7 (6%)
. 15 months: 3 (2%)
128 Analysed intention-to-treat
. 61 Excluded from per-protocol analysis
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Fig. 1 Flow of participants from screening to analysis, comparing mindfulness-based cognitive therapy (MBCT) followed by discontinuation
of maintenance antidepressant medication (MBCT+discontinuation) with MBCT plus maintenance antidepressant medication (MBCT+mADM).
a. Patients with a relative preference for MBCT were included in the current trial, whereas patients with a relative preference for mADM were included in a parallel trial
(MBCT+mADM v. mADM alone).18
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To examine whether there was differential drop-out based on
relapse/recurrence, we assessed whether participants who did not
complete the entire follow-up period showed a higher rate of
relapse/recurrence at the last observation than individuals who
completed follow-up at the final assessment. In this procedure
we excluded the participants who dropped out before the first
follow-up assessment (n= 22 in the MBCT+discontination group
and n=19 in the MBCT+mADM group). Of all the patients with
one to four follow-up assessments, 9/33 (27%) had a relapse/
recurrence at the last assessment, and in the complete case group,
43/175 (25%) had a relapse/recurrence at 15-month follow-up.
These proportions were comparable (w2 = 0.12, P= 0.74).
Secondary outcomes
Figure 3 shows the survival (i.e. non-relapse/recurrence) curves
over the 15-month follow-up period for the ITT and per-protocol
samples. The MBCT+discontinuation group was associated with
an increased relapse/recurrence risk over the 15-month follow-up
period (ITT: hazard ratio (HR)=1.59, 95% CI 1.10–2.31, P=0.01
and per-protocol: HR= 1.59, 95% CI 1.01–2.51, P=0.05). Results
were similar for analyses adjusted for baseline depression severity
and number of previous episodes. Results of the moderation
analyses are shown in online Table DS1. In summary, no
moderation effects of full v. partial remission, number of prior
depressive episodes (3 or 4 v. 5+), prior CBT or gender on the
effect of group were observed.
The latent growth curve analysis for severity of (residual)
depressive symptoms (IDS-C) over the 15-month follow-up
period showed an acceptable model fit, w2(d.f. = 20) = 39.85
(n=249), P=0.005, comparative fit index (CFI) = 0.95, root mean
square error of approximation (RMSEA) = 0.06, standardised root
mean square residual (SRMR)= 0.06. On average, patients
maintained mild levels of depression throughout the study period
(Fig. 4). The course of depression did not significantly vary
between the groups (b=70.05, P= 0.66 and b=70.10,
P= 0.43 for the ITT and per-protocol analyses, respectively).
However, when looking at the individual follow-up assessments
separately, the MBCT+discontinuation group had higher levels
of depression at 3-month follow-up (15.4) than the
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Fig. 2 Plot showing the differences in relapse/recurrence rates and corresponding one-sided 95% confidence intervals exceeding the
non-inferiority margin, for patients with recurrent depression receiving either mindfulness-based cognitive therapy (MBCT) followed by
discontinuation of maintenance antidepressant medication (MBCT+discontinuation group, n =128) or MBCT plus maintenance anti-
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Fig. 3 Survival curves over 15-month follow-up (65 weeks) for patients with recurrent depression receiving either mindfulness-based
cognitive therapy (MBCT) followed by discontinuation of maintenance antidepressant medication (MBCT+discontinuation, n =128) or MBCT
plus maintenance antidepressant medication (MBCT+mADM, n= 121).
(a) Intention-to-treat analysis, (b) per-protocol analysis.
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MBCT+mADM group (12.2). This difference was small but signif-
icant (F(188) = 5.8, P=0.02, d= 0.28). Depression levels did not
differ between groups at the other follow-up assessments. In the
per-protocol sample, there was a smaller difference at 3-month
follow-up, indicated by a trend (F(117) = 3.1, P=0.08, d= 0.20).
For those patients experiencing a relapse/recurrence, there
were no differences between the groups in terms of number of
relapses/recurrences (ITT: w2 = 0.02, P=0.89; per-protocol:
w2 = 1.43, P= 0.23), duration of (first) relapse (ITT: t= 0.03,
P= 0.97; per-protocol: t= 0.18, P= 0.86) or severity of (first)
relapse/recurrence (ITT: w2 = 1.07, P=0.59; per-protocol:
w2 = 3.32, P= 0.19). Online Table DS2 shows the results for the
analyses on quality of life. In summary, there were no differences
between the groups with regard to quality of life at 3-months and
15-months follow-up.
Discussion
Principal findings and comparison with other studies
This is the first study comparing MBCT followed by discontinuation
of mADM with the combination of these interventions
(MBCT+mADM). The findings of this effectiveness study reflect
an increased risk of relapse/recurrence for patients withdrawing
from mADM after having participated in MBCT for recurrent
depression. The overall course of depression severity during the
15-month follow-up period was similar in both groups, although
a small difference was observed at 3-month follow-up. At that
point, parallel with the moment of discontinuation, patients in the
withdrawal group had higher depression levels. In addition, this
study found no differences between the groups in terms of number,
duration and severity of relapse in those patients who relapsed.
Moreover, quality of life did not differ between the groups.
Our results seem to be in line with evidence that combination
therapy is more effective than monotherapy in the acute treatment
of major depressive disorder33 and also for prevention of relapse/
recurrence.34 On the other hand, earlier studies demonstrated that
the efficacy of MBCT followed by withdrawal from mADM,
performed in carefully controlled research circumstances, was
similar to that of mADM alone.15–17 These findings suggest that
MBCT might protect patients with recurrent depression from
relapse/recurrence. In those studies, the withdrawal process took
place as part of the intervention at the same time in the whole
group. Under those circumstances, there may have been more
emphasis on using mindfulness skills to accept the symptoms as
they were and to disengage from anticipatory fears and worries.
In contrast, MBCT was delivered in mixed groups in the current
study. Consequently, patients might have felt more insecure, have
lacked support compared with other studies and might even
have been actively discouraged to pursue discontinuation by
fellow-participants and/or their attending psychiatrists.
In addition, relapse/recurrence rates after discontinuation of
antidepressants were somewhat higher in the current study (ITT
54% and per-protocol 69%) compared with earlier studies reporting
estimates around 45% within 12–15 months.4,15,35 Participants in
the current study may have been more at risk for relapse as about
half of them were in partial (rather than full) remission and their
level of baseline depressive symptoms was relatively high, for
example compared with the studies by Kuyken and colleagues.15,17
In addition, a substantial number of the participants in this trial
were reluctant to discontinue their mADM, partly based on
previous unsuccessful attempts to do so, as were their attending
psychiatrists. So, adherence to the discontinuation protocol was
substantially lower in our study (53%) than in the studies by
Kuyken and colleagues (75% and 71%).15,17 Patients who were
not willing to withdraw may have been sensible to do so, given
their higher levels of baseline depression in comparison with those
who adhered to the protocol. On the other hand, previous studies
have shown that discontinuation of antidepressants can be
hampered by withdrawal effects36,37 that may be misinterpreted
as signs of a possible relapse/recurrence.38,39
Strengths and limitations
The great strength of the study is that MBCT was delivered in a
‘real-life’ setting, from university hospitals to community mental
health centres across The Netherlands, by teachers with varying
experience and competence, and in groups mixed with other types
of patients. In addition to the standard dichotomous classification
of relapse/recurrence we also assessed depressive symptoms over
time as a continuous measure. In contrast with the higher
relapse/recurrence rate, the overall course of depressive symptoms
was similar between groups. This raises the question what
parameter might be the better measure of the patients’ suffering.
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Fig. 4 Severity of (residual) depressive symptoms over 15-month follow-up for patients with recurrent depression receiving either
mindfulness-based cognitive therapy (MBCT) followed by discontinuation of maintenance antidepressant medication (MBCT+discontinuation,
n = 128) or MBCT plus maintenance antidepressant medication (MBCT+mADM, n= 121).
(a) Intention-to-treat analysis, (b) per-protocol analysis.
Inventory of Depressive Symptomatology – Clinician rated (IDS-C) cut-off points for depression severity: 0–11 none, 12–23 mild, 24–36 moderate, 37–46 severe and 47–84 very severe.
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Some authors have argued for the latter.40,41 A limitation of our
approach was that the intervals between assessments were
relatively long and that we did not include a self-report measure
of depression.
In terms of patient selection, a limitation of the current study
is that the results may apply to patients in secondary and tertiary
care, but cannot be assumed to extrapolate to primary care
patients or patients with less severe forms of depression.
Discontinuation may be particularly unfavourable for patients
who are at highest risk for relapse/recurrence because of residual
symptoms and several previous episodes, as sampled in the
current study.
A methodological limitation was that it was practically
impossible to keep the research assistants at the different sites
masked to group. However, a substantial interrater agreement
(k= 0.70) was found for the primary outcome measure (relapse/
recurrence according to SCID-I) when compared with a second
rater who was truly masked to group. Moreover, the relapse/
recurrence rates in ITT analysis may have been biased because of
incomplete follow-ups, assuming no relapse at the time of
censoring. Estimates obtained from complete case analysis were
higher, i.e. 61/92 (66%) relapse/recurrence in the MBCT+
discontinuation group and 40/83 (48%) in the MBCT+mADM
group, and probably more realistic.
Clinical and research implications
In summary, in routine clinical practice, patients with recurrent
depression should be generally recommended to stay on medication
and be informed that discontinuation of mADM may be associated
with an increased risk of relapse/recurrence. This does not
necessarily mean, however, that patients who do want to
discontinue their mADM should not be supported to have a try
or that they could not benefit from MBCT. A recommendation
for future research and clinical practice would be to ensure that
the clinician who supports the process of discontinuation is also
trained in the mindfulness model so that the difficulties that come
up can be managed within this framework. Given the many
psychological factors that may influence discontinuation,
placebo-controlled studies might inform us on the relative
contributions of physical and psychological barriers that patients
encounter. In addition, further qualitative research on the barriers
and facilitators that patients experience during the discontinuation
process might help us to better tailor our interventions to support
them.
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Table DS1 Cox regression proportional hazards analyses for time to relapse/recurrence in 
patients with recurrent depression receiving mindfulness-based cognitive therapy followed 
by discontinuation of maintenance antidepressant medication (MBCT+discontinuation) or 
mindfulness-based cognitive therapy plus maintenance antidepressant medication 
(MBCT+mADM), with moderator variables of interest 
 
Variable Intention-to-treat analysis 
(N=249) 
Per-protocol analysis 
(N=135) 
 Hazard 
ratio 
95% 
confidence 
interval 
p Hazard 
ratio  
95% 
confidence 
interval 
p 
Condition 
(MBCT+Discontinuation 
vs. MBCT+mADM) 
1.59  1.10 to 
2.31 
.01 1.59  1.01 to 
2.51 
.05 
Condition, adjusteda 1.60  1.11 to 
2.33 
.01 1.69  1.07 to 
2.68 
.03 
Remission (full vs. partial) 0.64  0.45 to 
0.93 
.02 0.61  0.39 to 
0.96 
.03 
 Remission x Condition 1.17  0.55 to 
2.45 
.69 1.06  0.42 to 
2.67 
.91 
Nr of episodes (3–4 vs. 5+) 1.00  0.70 to 
1.44 
.99 0.91  0.58 to 
1.43 
.69 
 Episodes x Condition 0.58  0.28 to 
1.23 
.16 0.93  0.37 to 
2.32 
.88 
Prior CBT (no vs. yes) 0.68  0.46 to 
1.00 
.05 0.73  0.46 to 
1.15 
.17 
 CBT x Condition 0.70  0.32 to 
1.52 
.36 0.56  0.22 to 
1.43 
.22 
Gender (male vs. female) 0.75  0.50 to 
1.11 
.15 0.81  0.50 to 
1.32 
.40 
 Gender x Condition 0.61  0.27 to 
1.35 
.22 0.50  0.18 to 
1.38 
.18 
 
CBT, cognitive-behavioural therapy. 
a. Adjusted for depressive symptoms (Inventory of Depressive Symptomatology, Clinican 
Rated) at baseline and number of depressive episodes in the past.   
 
Table DS2 Quality of life for the MBCT+Discontinuation group (N=128) and 
MBCT+mADM group (N=121) at baseline, 3 and 15 months. 
Variable Baseline 3 months 15 months   
 Mean (SD) N Mean (SD) N Mean (SD) N p a p b 
WHO-QoL – Q1: overall 
perception of quality of life 
      .36 .24 
    MBCT+Discontinuation 3.5 (0.8) 116 3.4 (0.9) 93 3.6 (0.8) 83   
    MBCT+mADM 3.5 (0.8) 113 3.6 (0.8) 86 3.7 (0.9) 68   
WHO-QoL – Q2: overall 
perception of health 
      .55 .29 
    MBCT+Discontinuation 3.5 (1.0) 116 3.3 (1.0) 92 3.4 (1.0) 83   
    MBCT+mADM 3.4 (1.0) 113 3.3 (1.0) 85 3.4 (1.1) 68   
WHO-QoL – physical 
domain 
      .48 .36 
    MBCT+Discontinuation 24.6 (4.3) 116 24.4 (4.5) 93 25.4 (4.9) 83   
    MBCT+mADM 24.2 (4.4) 113 24.6 (4.7) 86 25.6 (4.5) 67   
WHO-QoL – psychological 
domain 
      .21 .22 
    MBCT+Discontinuation 19.1 (3.1) 116 18.8 (3.7) 93 19.7 (3.6) 82   
    MBCT+mADM 18.7 (3.2) 113 19.9 (3.6) 86 20.0 (3.8) 68   
WHO-QoL – social domain       .94 .60 
    MBCT+Discontinuation 10.1 (2.2) 115 10.1 (2.1) 93 10.5 (2.3) 83   
    MBCT+mADM 9.8 (2.2) 113 10.0 (2.2) 86 10.1 (2.2) 68   
WHO-QoL – environmental 
domain 
      .60 .65 
    MBCT+Discontinuation 30.9 (4.2) 115 30.7 (4.9) 93 31.6 (4.5) 83   
    MBCT+mADM 30.6 (4.0) 113 30.5 (4.2) 86 31.9 (4.0) 68   
WHO-QoL = WHO Quality of Life. a p-value reported for the repeated measures analysis on condition – time 
interaction based on observed data. b p-value reported for the repeated measures analysis on condition – time 
interaction based on imputed data. 
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